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Accumulating evidence suggests an important role for cyclooxygenase-2 (COX-2) in the pathogenesis of a wide range of malig-
nancies. The protumorigenic properties of COX-2 are generally thought to be mediated by its product, PGE2, which is shown
to promote tumor spread and growth by multiple mechanisms but most importantly through modulation of the local immune
response in the tumor. Pancreatic tumor cells produce various amounts of PGE2, some of them being even deﬁcient in COX
enzymes or other PGE2 synthases. Here we describe that, beside pancreatic tumor cells or stromal ﬁbroblasts, human peripheral
blood mononuclear cells can also produce PGE2 upon coculture with pancreatic cancer cells. Stimulating of cellular cPLA2 within
PBMCs by secreted factors, presumably sPLA2, from tumor cells appeared crucial, while the direct contact between PBMCs and
PDACs seemed to be dispensable for this eﬀect. Our data is emphasizing the complex interactions participating in the formation
of the tolerogenic immune milieu within pancreatic tumors.
1.Introduction
Pancreaticductaladenocarcinoma(PDAC)isoneofthemost
lethal gastrointestinal malignancies. It is the fourth most
frequent cause of cancer-related deaths in North America,
the sixth in Europe, and the ﬁfth in the UK [1].
Beside surgery and chemotherapy, cyclooxygenases
(COX)—the constitutive (COX-1) and the inducible (COX-
2)—have been investigated as targets for treatment and
prevention of pancreatic cancer since their expression seems
tocorrelatewithpoorprognosisinPDACpatients[2,3].The
two forms of COX catalyze the conversion of arachidonic
acid (produced by the activity of phospholipase A2 and
other enzymes) into prostaglandins [4]. One of the main
representatives of prostaglandins is PGE2,c h a r a c t e r i z e da s
a mediator with suppressive activity at several levels of
the immune response [5]. It selectively impairs the pro-
duction of interleukin-2 (IL-2) and interferon-γ (IFNγ)
in T cells, blocks the production of dendritic-cell- (DC-)
produced proinﬂammatory cytokines, including IL-12p70,
and induces IL-10 production [6–8]. Earlier results suggest
an involvement of COX-2 in the control of tumor-dependent
angiogenesis and growth in certain pancreatic cancers and
providetherationaleforinhibitionoftheCOXpathwayasan
eﬀective therapeutic approach for pancreatic tumors [3, 9].
In addition, cyclooxygenase-2 (COX-2) overexpression in
transgenic mice induces a sequence of metaplasia-dysplasia
events leading to neoplastic transformation in the exocrine
pancreas [10].
Several works have focused on the production of PGE2
and the activity of enzymes involved in the earlier steps of
prostaglandin production in pancreatic cancer [11, 12].
Diagnostically, PGE2 levels have been shown to be helpful
to distinguish early intraductal papillary neoplasms (high
PGE2) from cystic neoplasms (low PGE2) in patients with
known mucinous lesions in the pancreas [13]. Investigations
report that either COX-1 or both COX-1 and COX-2
genes can be silenced in pancreatic cancers. Furthermore,
recent evidence supports that pancreatic cancers lacking
COX enzymes can exploit stromal ﬁbroblasts as an exoge-
nous source of prostaglandins and PGE2 in particular [11,
14]. Such ﬁbroblasts named also pancreatic stellate cells
(PSCs) promote the progression of pancreatic cancer by
increasing cancer cells’ proliferation and invasion, as well2 Journal of Oncology
as by protecting them from radiation- and gemcitabine-
induced apoptosis. However, it has to be noted that, beside
PSCs, other cells types such as macrophages, dendritic
cells, and lymphocytes that inﬁltrate pancreatic carcinoma
tissue actively participate in the formation of the cellular
and cytokine milieu within the tumor [15]. These cells
are considered to be quickly suppressed by the tolerogenic
microenvironment of the PDAC tumor, for which PGE2
seems to play an important role [16]. In addition, recent
work showed that PGE2 present in the PDAC patients’
plasma was involved in the induction of semimature DC
phenotype that does not allow these cells to function as
professional antigen-presenting cells [17].
In our work, we describe that the culture of human
pancreatic cancer cells (or their conditioned media) with
peripheral blood mononuclear cells induces the release of
PGE2 irrespective of the COX status and PGE2 producing
capacity of the PDAC cell line used in the assay.
2.MaterialsandMethods
2.1. Cells and Treatment. Human pancreatic carcinoma cell
lineswereobtainedfromATCC(Manassas,VA)andgrownin
RPMI1640(BxPC-3,T3M-4,AsPC-1)orDMEM(MiaPaCa-
2) supplemented with 10% fetal calf serum (FCS), penicillin
(100U/mL), and streptomycin (100μg/mL).
Buﬀy coats of randomly selected healthy donors were
obtained from the blood bank of the Heidelberg University,
and peripheral blood mononuclear cells (PBMCs) were
isolated by centrifugation over Histopaque 1077 gradient
(Sigma, Hamburg, Germany), at 400g, no brake, for
45min at room temperature. Cells were cultured in RPMI
supplemented with 10% FCS and penicillin (100U/mL)/
streptomycin (100μg/mL) at 37◦C, in a 5% CO2 incubator.
For corresponding experiments cells were simultaneously
stimulated using LPS and ConA (Sigma) both at ﬁnal
concentration of 5μg/mL.
The supernatants for either PDAC cells or PBMCs were
obtained after centrifugation at 10000rpm for 5 minutes
before application onto the cells or use for PGE2 ELISA
experiments.
The PLA2 inhibitor N-{(2S,4R)-4-(Biphenyl-2-ylmeth-
yl-isobutyl-amino)-1-[2-(2,4-diﬂuorobenzoyl)-benzoyl]-p-
yrrolidin-2-ylmethyl}-3-[4-(2,4-dioxothiazolidin-5 ylidene-
methyl)-phenyl]acrylamide (Pyrrolidin 1) was obtained
from Merck Biosciences, Germany and used at a ﬁnal con-
centration of 1μM. The sPLA2 inhibitor 4-[(1-oxo-7-
phenylheptyl)amino]-(4R)-octanoic acid (CAY10590) was
used at ﬁnal concentration of 91μM. The COX-1 inhibitor
SC-560, was used at a ﬁnal concentration of 10nM. The
COX-2 inhibitor NS-398 was used at a ﬁnal concentration of
2μM. CAY10590, SC-560, and NS-398 were obtained from
Cayman chemical, USA.
2.2. PGE2 Detection. The PGE2 measurement in culture
media was performed using a PGE2 ELISA kit obtained from
Enzo Life Sciences GmbH (L¨ orrach, Germany) following
manufacturer’s instructions. Experiments were repeated in
triplicate with at least three diﬀerent blood donors, and
statistical signiﬁcance was calculated using paired Student’s
t-test.
3. Results and Discussion
3.1. Pancreatic Cancer Cells Induce the Production of PGE2
from Human Peripheral Blood Mononuclear Cells. In our
study we used several human pancreatic cancer cell lines
from primary (MiaPaCa-2, BxPC-3) and metastatic origin
(AsPC-1, T3M-4) that have been previously characterized
to have various expression of the enzymes involved in PGE2
production. BxPC-3 have been formerly reported to intrin-
sically produce PGE2, since they are endowed with several
active elements of the PGE2 enzymatic cascade, namely,
cPLA2,C O X - 1 ,a n dC O X - 2[ 12]. On the other hand in
the same study MiaPaCa-2 and AsPC-1 were shown to be
deﬁcient in the expression of these enzymes and therefore
unable to produce PGE2. The cell line T3M-4 derives from
ametastatictumorandhasnotbeenpreviouslycharacterized
in terms of its PGE2 production status.
We tested the expression of PGE2 from these cells and
found that AsPC-1 and MiaPaCa-2 did not produce any
PGE2 after 48 hours of cultivation (Figure 1(a)). In contrast
both BxPC-3 and T3M-4 could release signiﬁcant amounts
of this prostaglandin. Nonstimulated mononuclear cells
from peripheral blood did not secrete PGE2 under normal
culture conditions but could be strongly induced to release it
upon treatment with LPS and ConA (Figure 1(b)). Plating
of unstimulated PBMCs together with pancreatic cancer
cells caused a burst of PGE2 activity in the medium 48
hours after coculturing the cells. The levels were comparable
in all four cocultures reaching the amounts obtained after
LPS/ConA stimulation (Figure 1(b)). While in the case of
BxPC-3 and T3M-4, pancreatic cells could have actively
contributedtotheincreaseinPGE2 concentration,forAsPC-
1 and MiaPaCa-2 this was rather unlikely, since they were
reported as completely devoid of PGE2 synthases and did not
produce any PGE2 in our experiments. Therefore, PBMCs
seemed to be the only possible source of the prostaglandin
within these cocultures.
3.2. Production of PGE2 from PBMCs Is Induced by Factor(s)
Secreted by Pancreatic Cancer Cells. In our next step we
aimed at establishing whether PGE2 production may be
induced by a factor secreted by tumor cells or whether
it requires direct cell to cell contact. Supernatants from
cultured pancreatic cancer cells were applied onto preseeded
PBMCs. We selected to use conditioned media from AsPC-
1 and MiaPaCa-2 cells since, as already determined above,
these cells were unable to produce PGE2 on their own.
As shown in Figure 2, LPS/ConA treatment induced a very
potent PGE2 response from PBMCs. The supernatants of
AsPC-1 and MiaPaCa-2 could also provoke the release
of signiﬁcant amount of the prostaglandin from PBMCs,
although to a lesser extent (Figure 2). We reconﬁrmed that
the media of AsPC-1 and MiaPaCa-2 were devoid of any
PGE2 before being applied onto the PBMCs (data not
shown). In conclusion, these data suggest that direct cellJournal of Oncology 3
Table 1: PGE2 production from PBMCs in presence of supernatants from PDAC cell lines and speciﬁc inhibitors.
Treatment Inhibitors
No inh. cPLA2 sPLA2 COX-1 COX-2
PBMC + AsPC-1 SN1 100% ±08 .84% ±5.64∗ 3.50% ±2.94∗ 100% ±81.16 1.99% ±1.82∗
PBMC + MiaPaCa-2 SN1 100% ±01 4 .40% ±2.5∗ 6.02% ±2.06∗ 68.69% ±29.58 2.89% ±1.58∗
PGE2 production was measured in the coculture supernatants 48 hours posttreatment. Data are represented as percentages of PGE2 production, compared
to that induced by PDAC supernatants on PBMCs (taken as 100%) plus. The names and concentrations of respective inhibitors are indicated in Materials
and Methods. The experiment was repeated with four independent donors. Standard error was calculated using SigmaPlot 10.1 program, and the statistical
signiﬁcance (∗)o fd i ﬀerences was assessed by a two-tailed Student’s paired t-test. P values below 0.05 were considered signiﬁcant.
1SN-supernatant.
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Figure 1: Release of PGE2 from pancreatic carcinoma cells and
peripheral blood mononuclear cells. (a) PGE2 production from
PDAC monocultures of cells. Cells (AsPC-1, MiaPaCa-2, T3M-
4, BxPC-3) were plated in 48-well plates at a density of 2.5 ×
104 cells/well in 500μL of medium/well, and supernatants were
collected at 48hrs for PGE2 ELISA measurement. (b) PGE2 pro-
ductionfromPBMCs.AfterpuriﬁcationoveraHistopaquegradient
mononuclear cells were plated in a 48-well plate (5 × 105 cells/well)
either alone or onto preseeded PDAC cultures (2.5×104 cells/well).
48 hours after coculturing the cells, supernatants were collected and
analysed for PGE2 expression. PBMCs treated with LPS and ConA
served as controls. All experiments were repeated in triplicate with
three diﬀerent healthy blood donors. ∗Standard deviations were
calculated, and results were considered signiﬁcant with P values
from Student’s t-test below 0.05.
contact between PBMCs and PDACs is dispensable for PGE2
induction from immune cells.
The ﬁrst enzymatic activity required for prostaglandin
production is phospholipase A2, which among other
enzymes catalyzes the release of arachidonic acid from cell
membrane lipids [4]. This enzyme has several forms, the
most potent being the cytoplasmic phospholipase A2
(cPLA2) [18] that can potentially be activated in PBMCs
by PDACs or their secreted factors to induce PGE2 release.
For that purpose we treated the immune cell cultures with
a selective cPLA2 inhibitor (pyrolidin 1) [19] immediately
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Figure 2:ReleaseofPGE2 fromperipheralbloodmononuclearcells
treated with PDAC supernatants. Supernatants (SN) from AsPC-1
and MiaPaCa-2 cells, derived 24hrs after plating of the cells, were
treated (SN + cPLA2 Inh.) or not (SN) with Pyrolidin 1 and applied
onto cultured PBMCs (1 × 106 cells/well) in a 24 well plate. Two
partsofPD A Cmedium(400μL)wereaddedontoonepartmedium
overlaying the PBMCs (200μL) and 48hrs later samples were
collected and analysed for PGE2 expression. The experiment was
repeated in duplicate with three diﬀerent healthy blood donors.
∗Standard deviations were calculated and results were considered
signiﬁcant with P values from Student’s t-test below 0.05.
after application of the conditioned AsPC-1 and MiaPaCa-2
media. The presence of the inhibitor could drastically reduce
PGE2 production induced by pancreatic cancer supernatants
(Figure 2), suggesting indeed that the inherent cPLA2 activ-
ity in PBMCs is triggered by factors secreted by pancreatic
cancer cells. Given that sPLA2 may trigger PGE2 production,
although to a lesser extent than cPLA2, and taking into
account their known ability to stimulate the cPLA2 enzyme
[20, 21], we evaluated the eﬀect of diﬀerent inhibitors of
the PGE2 production cascade in cultures of human PBMCs
treated with AsPC-1 and MiaPaCa-2 media. As shown in
Table 1 the COX-1 enzyme was not a major player contribut-
ing to PGE2 production form PBMCs, while COX-2 seemed
to be strongly involved in the latter process. Interestingly,
boththecPLA2andsPLA2inhibitorsseemedtohaveastrong
inhibitory eﬀect on PGE2 production, suggesting that sPLA2
enzymes most likely released from AsPC-1 and MiaPaCa-
2 could represent a potential candidate to indirectly trigger
PGE2 expression.
Very recent study by Omura et al. [11]a sw e l la se a r l i e r
reports [14] has proposed that cancer-associated ﬁbroblasts,
representingthehighestpercentageofpancreaticcancerstro-
mal cells, may serve as exogenous sources of prostaglandins
for cyclooxygenase-deﬁcient pancreatic cancers. In this study4 Journal of Oncology
we could conﬁrm our assumption that the immune com-
ponent, which is also widely represented in PDAC stromal
reaction, may represent an important alternative source of
prostaglandin production in the presence of tumor cells. For
instance,macrophagesanddendriticcellscouldbecomesuch
a source, since they are well known to produce high levels of
PGE2 upon stimulation [22, 23].
Omura et al. [11] have also demonstrated that, in some
of the clinical cancer samples and cell lines testing negative
for COX-1 mRNA, certain level of expression could still
be induced by epigenetic treatment with methyltransferase
inhibitor 5-aza-dC or histone deacetylase inhibitor TSA.
However, it is rather unlikely that in our coculture exper-
iments PBMCs could induce such a high level of PGE-2
expression from PDACs, following mechanisms similar to
chemical stimulation.
The levels of PGE2 induced by supernatants of AsPC-
1 and MiaPaCa-2 cells applied on the PBMCs were lower
than the ones achieved in the corresponding cocultures, but
one has to take into account that the concentrations of
the probable secreted stimulators should be much higher in
the immediate proximity of the cells than in the overlaying
medium that we used for the stimulation.
4. Conclusion
In our work we describe a previously unknown, feature of
pancreatic cancer stromal interaction, pointing that pancre-
atic cancer cells can induce PGE2 production from immune
cells and further modulate host cell functions in their favor
throughamechanismthatmayalsobecharacteristicofother
tumor entities.
Abbreviations
PDAC: Pancreatic ductal adenocarcinoma
COX: Cyclooxygenase
PBMCs: Peripheral blood mononuclear cells
PSC: Pancreatic stellate cells
PLA2: Phospholipase A2.
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